Benzinga | Jun 9, 2021 08:37AM EDT

Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose

* The FDA has accepted for review Adamis Pharmaceuticals Corporation's (NASDAQ:ADMP) marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose.

* The agency's target action date is November 12.

* The company resubmitted the application in May after it received a complete response letter in November 2020.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: ADMP shares are up 11.9% at $1.13 during the premarket session on the last check Wednesday.